Table 2

Frequency distributions of XPC genotypes and their associations with risk of lung cancer

Histologic type

Histologic type



XPC genotypes

Controls n (%)

Cases n (%)

Adenocarcinoma n (%)

Squamous cell n (%)

Small cell n (%)

All Cases OR (95% C.I.)

Adenocarcinoma OR (95% CI)

Squamous cell OR (95% CI)

Small cell OR (95% CI)


rs3731055

GG

512 (52.0)

541 (55.9)

247 (60.0)

174 (54.5)

24 (38.7)

1.00

1.00

1.00

1.00

AG

404 (41.0)

366 (37.8)

141 (34.2)

126 (39.4)

31 (50.0)

0.83 (0.69–1.01)

0.71 (0.56–0.92)**

0.90 (0.68–1.20)

1.69 (0.97–2.96)

AA

69 (7.0)

60 (6.3)

24 (5.8)*

20 (6.2)

7 (11.3)

0.76 (0.52–1.11)

0.67 (0.41–1.10)

0.83 (0.47–1.45)

2.44 (0.99–6.02)

AG+AA

473 (48.0)

426 (44.1)

165 (40.0)

146 (45.5)

38 (61.3)

0.82 (0.68–0.99)*

0.71 (0.56–0.90)**

0.86 (0.66–1.13)

1.79 (1.05–3.07)*

A MAFa

27.5%

25.1%

22.9%*

25.9%

36.2%*

rs2607775

CC

925 (93.1)

913 (92.0)

390 (92.2)

306 (92.7)

58 (90.6)

1.00

1.00

1.00

1.00

CG

65 (6.5)

77 (7.8)

31 (7.3)

24 (7.3)

6 (9.4)

1.16 (0.82–1.66)

1.06 (0.67–1.67)

1.08 (0.64–1.81)

1.16 (0.47–2.88)

GG

4 (0.4)

2 (0.2)

2 (0.5)

0 (0.0)

0 (0.0)

0.78 (0.14–4.34)

1.60 (0.28–9.02)

---

---

CG+GG

69 (6.9)

79 (8.0)

33 (7.8)

24 (7.3)

6 (9.4)

1.15 (0.81–1.62)

1.10 (0.71–1.72)

1.08 (0.64–1.81)

1.16 (0.47–2.88)

G MAFa

3.7%

4.1%

4.1%

3.6%

4.7%

rs2228000

CC

446 (45.1)

452 (45.5)

184 (43.3)

149 (44.9)

31 (48.4)

1.00

1.00

1.00

1.00

CT

456 (46.1)

435 (43.8)

193 (45.4)

149 (44.9)

25 (39.1)

0.98 (0.81–1.19)

1.05 (0.82–1.35)

1.01 (0.77–1.34)

0.79 (0.46–1.38)

TT

88 (8.8)

107 (10.7)

48 (11.3)

34 (10.2)

8 (12.5)

1.28 (0.93–1.77)

1.42 (0.95–2.13)

1.20 (0.75–1.92)

1.37 (0.59–3.14)

CT+TT

544 (54.9)

542 (54.5)

241 (66.7)

183 (55.1)

33 (51.6)

1.03 (0.86–1.24)

1.11 (0.88–1.40)

1.04 (0.80–1.36)

0.88 (0.53–1.48)

T MAFa

31.9%

32.6%

34.0%

32.7%

32.0%

rs2228001

AA

404 (40.7)

390 (39.4)

163 (38.3)

129 (39.2)

30 (47.6)

1.00

1.00

1.00

1.00

AC

465 (46.9)

459 (46.3)

198 (46.5)

153 (46.5)

28 (44.4)

1.01 (0.83–1.22)

1.03 (0.80–1.33)

1.04 (0.78–1.38)

0.80 (0.47–1.38)

CC

123 (12.4)

142 (14.3)

65 (15.2)

47 (14.3)

5 (8.0)

1.17 (0.88–1.56)

1.31 (0.92–1.88)

1.14 (0.75–1.72)

0.53 (0.20–1.40)

AC+CC

588 (59.3)

601 (60.6)

263 (61.7)

200 (60.8)

33 (52.8)

1.04 (0.87–1.25)

1.09 (0.86–1.38)

1.06 (0.81–1.39)

0.74 (0.44–1.25)

C MAFa

35.8%

37.5%

38.5%

37.5%

30.1%

rs3729587

CC

768 (82.3)

756 (80.8)

329 (82.4)

260 (84.1)

47 (81.0)

1.00

1.00

1.00

1.00

CG

130 (14.0)

149 (15.9)

59 (14.8)

42 (13.3)

9 (15.5)

1.14 (0.88–1.48)

1.09 (0.77–1.53)

0.93 (0.62–1.38)

1.09 (0.52–2.32)

GG

35 (3.7)

31 (3.3)

12 (2.8)

8 (2.6)

2 (3.5)

0.90 (0.54–1.50)

0.82 (0.41–1.61)

0.59 (0.26–1.33)

0.86 (0.20–3.78)

CG+GG

165 (17.7)

180 (19.2)

71 (17.6)

50 (15.9)

11 (19.0)

1.09 (0.86–1.39)

1.03 (0.75–1.41)

0.85 (0.59–1.23)

1.04 (0.52–2.08)

G MAFa

10.7%

11.3%

10.4%

9.3%

11.2%


a MAF: minor allele frequency

*P < 0.05; **P < 0.01.

Bai et al. BMC Cancer 2007 7:81   doi:10.1186/1471-2407-7-81

Open Data